Discussion of ABC7 Consensus and German Recommendations

Michael Untch; Nina Ditsch; Peter A. Fasching; Steffi Busch; Johannes Ettl; Renate Haidinger; Nadia Harbeck; Christian Jackisch; Diana Lüftner; Lothar Müller; Eugen Ruckhäberle; Eva Schumacher-Wulf; Christoph Thomssen; Rachel Wuerstlein; Volkmar Müller

doi:10.1055/a-2263-5152

Geburtshilfe und Frauenheilkunde, Table of Contents

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2024; 84(05): 431-442
DOI: 10.1055/a-2263-5152

GebFra Science

Review/Übersicht

Discussion of ABC7 Consensus and German Recommendations

Article in several languages: English | deutsch

Authors

Michael Untch

¹Klinik für Gynäkologie und Geburtshilfe, interdisziplinäres Brustzentrum, HELIOS Klinikum Berlin Buch, Berlin, Germany
Nina Ditsch

²Klinik für Frauenheilkunde und Geburtshilfe, Brustzentrum, Universitätsklinikum Augsburg, Augsburg, Germany
Peter A. Fasching

³Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Steffi Busch

⁴Onkologische Schwerpunktpraxis, Dr. Busch MVZ GmbH, Mühlhausen,Germany
Johannes Ettl

⁵Klinik für Gynäkologie und Geburtshilfe, Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikverbund Allgäu gGmbH, Klinikum Kempten, Kempten, Germany
Renate Haidinger

⁶Brustkrebs Deutschland e. V., Hohenbrunn, Germany; patient advocate, board member ABC Global Alliance
Nadia Harbeck

⁷Brustzentrum, Frauenklinik und Comprehensive Cancer Center (CCC), LMU Klinikum München, München, Germany; ABC7 panel member
Christian Jackisch

⁸Klinik für Gynäkologie und Frauenheilkunde, Sana Klinikum Offenbach, Offenbach, Germany
Diana Lüftner

⁹Immanuel Klinik Märkische Schweiz, Buckow & Immanuel Klinik Rüdersdorf, Medizinische Hochschule Brandenburg, Rüdersdorf bei Berlin, Germany
Lothar Müller

¹⁰Onkologie UnterEms, Studienzentrum UnterEms, Leer, Germany
Eugen Ruckhäberle

¹¹Universitätsfrauenklinik, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
Eva Schumacher-Wulf

¹²Mamma Mia! Brustkrebsmagazin, Köln, Germany; patient advocate, co-chair, ABC7 panel member
Christoph Thomssen

¹³Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany
Rachel Wuerstlein

¹⁴Brustzentrum, Frauenklinik und Comprehensive Cancer Center (CCC), LMU Klinikum München, München, Germany
Volkmar Müller

¹⁵Klinik und Poliklinik für Gynäkologie, Universitätsfrauenklinik und Brustzentrum Hamburg-Eppendorf, Hamburg Germany; ABC7 panel member

Abstract

The rationale behind the “International Consensus Conference for Advanced Breast Cancer” (ABC) is to standardize the treatment of patients with advanced or metastatic breast cancer worldwide using an evidence-based approach. The aim is also to ensure that patients in all countries receive adequate treatment based on current treatment recommendations and standards. The 7th International Consensus Conference on Advanced Breast Cancer (ABC7) took place from November 9 to 12, 2023 in Lisbon/Portugal. ABC7 focused on metastatic disease as well as on locally advanced and inflammatory breast cancer. Special topics included the treatment of oligometastatic patients, leptomeningeal disease, treatment of brain metastases, and pregnant women with ABC. As in previous years, patient advocates from all over the world participated in the consensus conference and were involved in decision making.

Keywords

ABC and pregnancy - systemic therapy - ADCs - oligometastases - brain metastases - leptomeningeal disease

Full Text

References

References/Literatur
1 Thill M, Kolberg-Liedtke C, Albert U-S. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18: 306-315
2 Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001; 33: 139-144
3 Kowalski ES, Feigenberg SJ, Cohen J. et al. Optimal Target Delineation and Treatment Techniques in the Era of Conformal Photon and Proton Breast and Regional Nodal Irradiation. Pract Radiat Oncol 2020; 10: 174-182
4 Davidson T, Ben-David M, Galper S. et al. Use of 18F-FDG PET-CT imaging to determine internal mammary lymph node location for radiation therapy treatment planning in breast cancer patients. Pract Radiat Oncol 2017; 7: 373-381
5 Jacene HA, DiPiro PJ, Bellon J. et al. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat 2020; 181: 383-390
6 Schmid P, Cortes J, Dent R. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; 386: 556-567
7 Cortes J, Rugo HS, Cescon DW. et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022; 387: 217-226
8 Maio M, Shapira-Frommer R, Yap TA. et al. Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study. Cancer Research 2021; 81: CT178
9 Rugo H, Robson M, Im SA. Pembrolizumab Plus Olaparib vs. Pembrolizumab Plus Chemotherpy After Induction With Pembrolizumab Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized, Open-Label, Phase 2 KEYLYNK-009 Study. San Antonio Breast Cancer Symposium (SABCS) 2023, San Antonio, 05 – 09th Decembre 2023. Presentation GS01-05.
10 Azim H, El Saghir NS, Yap Y. et al. First-line ribociclib + endocrine therapy vs. combination chemotherapy in aggressive HR+/HER2- advanced breast cancer: a sub-group analysis of patients with or without vis-ceral crisis from the phase II RIGHT Choice study. Präsentation 402P. Accessed April 16, 2024 at: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/first-line-ribociclib-rib-endocrine-therapy-et-vs-combination-chemotherapy-combo-ct-in-aggressive-hr-her2-advanced-breast-cancer-abc-a
11 Wolff AC, Somerfield MR, Dowsett M. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2023; 147: 993-1000
12 Sonke GS, van Ommen-Nijhof A, Wortelboer N. et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol 2023; 41: LBA1000
13 Decker T, Lüdtke-Heckenkamp K, Melnichuk L. et al. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA). Breast 2023; 72: 103575
14 Kalinsky K, Accordino MK, Chiuzan C. et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol 2023; 41: 4004-4013
15 Bidard F-C, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256
16 Bidard F-C, Kaklamani VG, Neven P. et al. Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2023; 41: 3962
17 Kaklamani V, Bidard FC, Neven P. et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2– metastatic breast cancer: Updated re-sults by duration of prior CDK4/6 inhibitor in metastatic setting. 2022 San Antonio Breast Cancer Symposium. Abstract GS3-01. Presented December 8, 2022.
18 Turner NC, Oliveira M, Howell SJ. et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388: 2058-2070
19 Rugo HS, Bardia A, Marmé F. et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2022; 40: 3365-3376
20 Rugo HS, Bardia A, Marmé F. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1423-1433
21 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20
22 Bardia A, Hurvitz SA, Tolaney SM. et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529-1541
23 Modi S, Andre F, Krop IE. et al. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. J Clin Oncol 2020; 38: 1036
24 Hurvitz SA, Hegg R, Chung W-P. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023; 401: 105-117
25 André F, Hee Park Y, Kim S-B. et al. Trastuzumab deruxtecan versus treatment of physicianʼs choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 401: 1773-1785
26 Hurvitz S, Modi S, Li W. et al. A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases from DESTINY-Breast01, -02 and -03. ESMO-Jahrestagung 2023, Madrid. Oral presentation #377PPS2023.
27 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
28 Chmura SJ, Winter KA, Woodward WA. et al. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol 2022; 40: 1007
29 Dunst J. Kurative Strahlentherapie von Oligometastasen: Langzeitergebnisse der SABR-COMET-Studie. Strahlenther Onkol 2021; 197: 365-367
30 Cardoso F, Costa A, Senkus E. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC3). Ann Oncol 2017; 28: 16-33
31 Biganzoli L, Battisti NML, Wildiers H. et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol 2021; 22: e327-e340
32 Martinez-Tapia C, Paillaud E, Liuu E. et al. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. Eur J Cancer 2017; 83: 211-219
33 Decoster L, van Puyvelde K, Mohile S. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 2015; 26: 288-300
34 El Badri S, Tahir B, Balachandran K. et al. Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. Breast 2021; 60: 199-205
35 Carola E, Pulido M, Falandry C. et al. First-line systemic treatment with palbociclib in women aged ≥ 70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program. J Clin Oncol 2023; 41: 1018
36 Blum JL, Rocque G, Ji Y. et al. Impact of comorbidities on real-world patient-reported outcomes of patients with hormone receptor positive human epidermal growth factor 2 negative advanced breast cancer enrolled in the POLARIS trial. ESMO-Jahrestagung 2023, Madrid 20.–24.10.2023. #461P 2023.
37 Tripathy D, Blum JL, Karuturi MS. et al. Impact of comorbidities on real-world clinical outcomes of patients with hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer treated with palbociclib and enrolled in POLARIS. ESMO-Jahrestagung 2023; Madrid, 20.–24.10.2023. #373P.
38 Roncato R, Angelini J, Pani A. et al. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. Int J Mol Sci 2020; 21